Drug manufacturer AstraZeneca and the federal government each told a federal district court last Friday why it, and not the other, should prevail in Astra’s lawsuit over the government’s 340B contract pharmacy requirements.
The Aug. 6 filings were the latest waypoint on the path toward a ruling on the legality of the government’s May 17 letter informing the company that its policy of denying 340B pricing when covered entities use contract pharmacies results in overcharges and violates the 340B statute. Astra and the government filed dueling briefs on July 23.
Drug manufacturer AstraZeneca and the federal government each told a federal district court last Friday why it, and not the other, should prevail in Astra’s lawsuit over the government’s 340B contract pharmacy requirements.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
